A "window of opportunity": The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent

Brain Research

Volumn 1379, Issue , 2011, Pages 244-252

  Hodis, Howard N ^a   Mack, Wendy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cognition; Coronary heart disease; Hormone therapy; Menopause; Meta analysis; Mortality; Prevention; Quality adjusted life year; Randomized controlled trial; Selective estrogen receptormodulator

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CORONARY ARTERY RECANALIZATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; GROUPS BY AGE; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; MORTALITY; NONFATAL MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION;

AGE FACTORS; ANIMALS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 79952311372     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.10.076     Document Type: Review

References (41)

1. Akhrass, F., Evans, A.T., Wang, Y., Stuart, R., Kannan, C.R., Fogelfeld, L., Mazzoneet, T., 2003. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J. Clin. Endocrinol. Metab. 88, 5611-5614.
2. Barrett-Connor, E., Laughlin, G.A., 2005. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 12, 40-48. (Pubitemid 40204892)
3. Berger, J.S., Roncaglioni, M.C., Avanzini, F., Pangrazzi, I., Tognoni, G., Brown, D.L., 2006. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295, 306-313.
4. Blankenhorn, D.H., Hodis, H.N., 1994. Duff Memorial Lecture: arterial imaging and atherosclerosis reversal. Arterioscler. Thromb. 14, 177-192.
5. Chilvers, C.E.D., Knibb, R.C., Armstrong, S.J., Woods, K.L., Logan, R.F.A., 2003. Postmenopausal hormone replacement therapy and risk of acute myocardial infarction: a case control study of women in the East Midlands, UK. Eur. Heart J. 24, 2197-2205.
6. Collins, P., Mosca, L., Geiger, M.J., Grady, D., Kornitzer, M., Amewou-Atisso, M.G., Effron, M.B., Dowsett, S.A., Barrett-Connor, E., Wenger, N.K., 2009. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors. Circulation 119, 922-930.
7. de Kleijn, M.J.J., Bots, M.L., Bak, A.A.A., Westendorp, I.C.D., Planellas, J., Bennink, H.J.C., Witteman, J.C.M., Grobbee, D.E., 1999. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas 32, 195-204. (Pubitemid 29389735)
8. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), 2001. JAMA 285, 2486-2497.
9. Falkeborn, M., Persson, I., Adami, H.O., 1992. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br. J. Obstet. Gynaecol. 99, 821-828.
10. Ferrara, A., Quesenberry, C.P., Karter, A.J., Njoroge, C.W., Jacobson, A.S., Selby, J.V., 2003. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente diabetes registry, 1995-1998. Circulation 107, 43-48. (Pubitemid 36070931)
11. Grodstein, F., Stampfer, M., 1995. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiol. Dis. 38, 199-210.
12. Grodstein, F., Stampfer, M., 1998. Estrogen for women at varying risk of coronary disease. Maturitas 30, 19-26. (Pubitemid 29027811)
13. Grodstein, F., Stampfer, M.J., Manson, J.E., Colditz, G.A., Willett, W.C., Rosner, B., Speizer, F.E., Hennekens, C.H., 1996. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335, 453-461.
14. Grodstein, F., Manson, J.E., Colditz, G.A., Willett, W.C., Speizer, F.E., Stampfer, M.J., 2000. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133, 933-941.
15. Heckbert, S.R., Weiss, N.S., Koepsell, T.D., Lemaitre, R.N., Smith, N.L., Siscovick, D.S., Lin, D., Psaty, B.M., 1997. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch. Intern. Med. 157, 1330-1336.
16. Henderson, B.D., Paganini-Hill, A., Ross, R.K., 1991. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151, 75-78.
17. Hodis, H.N., Mack, W.J., 2007a. Randomized controlled trials and the effects of postmenopausal hormone therapy on cardiovascular disease: facts, hypotheses and clinical perspective, In: Lobo, R.A. (Ed.), Treatment of the postmenopausal woman, 3rd ed. Elsevier, Philadelphia, PA, pp. 529-564.
18. Hodis, H.N., Mack, W.J., 2007b. Postmenopausal hormone therapy in clinical perspective. Menopause 14, 944-957. (Pubitemid 47517597)
19. Hodis, H.N., Mack, W.J., 2008. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin. Obstet. Gyencol. 51, 564-580.
20. Hodis, H.N., Mack, W.J., Lobo, R.A., Shoupe, D., Sevanian, A., Mahrer, P.R., Selzer, R.H., Liu, C.R., Liu, C.H., Azen, S.P., 2001. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135, 939-953.
21. Hodis, H.N., Mack, W.J., Azen, S.P., Lobo, R.A., Shoupe, D., Mahrer, P.R., Faxon, D.P., Cashin-Hemphill, L., Sanmarco, M.E., French, W.J., Shook, T.L., Gaarder, T.D., Mehra, A.O., Rabbani, R., Sevanian, A., Shil, A.B., Torres, M., Vogelbach, K.H., Selzer, R.H., 2003. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 349, 535-545.
22. Hsia, J., Langer, R.D., Manson, J.E., Kuller, L., Johnson, K.C., Hendrix, S.L., Pettinger, M., Heckbert, S.R., Greep, N., Crawford, S., Eaton, C.B., Kostis, J.B., Caralis, P., Prentice, R., 2006. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med. 166, 357-365.
23. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., Vittinghoff, E., 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280, 605-613. (Pubitemid 28502636)
24. Manson, J.E., Hsia, J., Johnson, K.C., Rossouw, J.E., Assaf, A.R., Lasser, N.L., Trevisan, M., Black, H.R., Heckbert, S.R., Detrano, R., Strickland, O.L., Wong, N.D., Crouse, J.R., Stein, E., Cushman, M., 2003. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523-534.
25. Manson, J.E., Allison, M.A., Rossouw, J.E., Carr, J.J., Langer, R.D., Hsia, J., Kuller, L.H., Cochrane, B.B., Hunt, J.R., Ludlam, S.E., Pettinger, M.B., Gass, M., Margolis, K.L., Nathan, L., Ockene, J.K., Prentice, R.L., Robbins, J., Stefanick, M.L., 2007. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591-2602.
26. Mosca, L., Appel, L.J., Benjamin, E.J., Berra, K., Chandra-Strobos, N., Fabunmi, R.P., Grady, D., Haan, C.K., Hayes, S.N., Judelson, D.R., Keenan, N.L., McBride, P., Oparil, S., Ouyang, P., Oz, M.C., Mendelsohn, M.E., Pasternak, R.C., Pinn, V.W., Robertson, R.M., Schenck- Gustafsson, K., Sila, C.A., Smith, S.C., Sopko, G., Taylor, A.L., Walsh, B.W., Wenger, N.K., Williamset, C.L., 2004. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109, 672-693. (Pubitemid 38198877)
27. Nelson, H.D., Vesco, K.K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., Humphrey, L., 2006. Nonhumoral therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 295, 2057-2071. (Pubitemid 44794007)
28. Ogawa, H., Nakayama, M., Morimoto, T., Uemura, S., Kanauchi, M., Doi, N., Jinnouchi, H., Sugiyama, S., Saito, Y., 2008. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300, 2134-2141.
29. Petretta, M., Costanzo, P., Perrone-Filardi, P., Chiariello, M., 2010. Impact of gender in primary prevention of coronaryheart disease with stain therapy: a meta-analysis. Int. J. Cardiol. 138, 25-31.
30. Prentice, R.L., Langer, R., Stefanick, M.L., Howard, B.V., Pettinger, M.L., Anderson, G.L., Barad, D., Curb, J.D., Kotchen, J., Kuller, L., Limacher, M., Wactawski-Wende, J., 2005. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am. J. Epidemiol. 162, 404-414.
31. Prentice, R.L., Langer, R., Stefanick, M.L., Howard, B.V., Pettinger, M., Anderson, G.L., Barad, D., Curb, J.D., Kotchen, J., Kuller, L., Limacher, M., Wactawski-Wende, J., 2006. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease. Am. J. Epidemiol. 163, 589-599.
32. Psaty, B.M., Heckbert, S.R., Atkins, D., Lemaitre, R.N., Koepsell, T.D., Wahl, P.W., Siscovick, D.S., Wagneret, E.H., 1994. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch. Intern. Med. 154, 1333-1339.
33. Ridker, P.M., Cook, N.R., Lee, I.M., Gordon, D., Gaziano, J.M., Manson, J.E., Hennekens, C.H., Buring, J.E., 2005. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304.
34. Rossouw, J.E., Prentice, R.L., Manson, J.A., Manson, J.E., Wu, L.L., Barad, D., Barnabei, V.M., Ko, M., LaCroix, A.Z., Margolis, K.L., Stefanick, M.L., 2007. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465-1477. (Pubitemid 46556472)
35. Salpeter, S.R., Walsh, J.M.E., Greyber, E., Ormiston, T.M., Salpeter, E.E., 2004. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J. Gen. Intern. Med. 19, 791-804.
36. Salpeter, S.R., Walsh, J.M.E., Greyber, E., Salpeter, E.E., 2006. Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J. Gen. Intern. Med. 21, 363-366.
37. Salpeter, S.R., Cheng, J., Thabane, L., Buckley, N.S., Salpeter, E.E., 2009a. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am. J. Med. 12, 1016-1022.
38. Salpeter, S.R., Buckley, N.S., Liu, H., Salpeter, E.E., 2009b. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am. J. Med. 122, 42-52.
39. Thompson, S.G., Meade, T.W., Greenberg, G., 1989. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J. Epidemiol. Community Health 43, 173-178. (Pubitemid 19147305)
40. Toh, S., Hernandez-Diaz, S., Logan, R., Rossouw, J.E., Hernan, M.A., 2010. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? Ann. Intern. Med. 152, 211-217.
41. Walsh, J.M.E., Pignone, M., 2004. Drug treatment of hyperlipidemia in women. JAMA 291, 2243-2252. (Pubitemid 38608174)